PL3636640T3 - Kryształ heterocyklidenowej pochodnej acetamidu - Google Patents
Kryształ heterocyklidenowej pochodnej acetamiduInfo
- Publication number
- PL3636640T3 PL3636640T3 PL18810263.6T PL18810263T PL3636640T3 PL 3636640 T3 PL3636640 T3 PL 3636640T3 PL 18810263 T PL18810263 T PL 18810263T PL 3636640 T3 PL3636640 T3 PL 3636640T3
- Authority
- PL
- Poland
- Prior art keywords
- crystal
- acetamide derivative
- heterocyclidene
- heterocyclidene acetamide
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512775P | 2017-05-31 | 2017-05-31 | |
| JP2017108017A JP6230743B1 (ja) | 2017-05-31 | 2017-05-31 | ヘテロシクリデンアセトアミド誘導体の結晶 |
| PCT/JP2018/020634 WO2018221543A1 (ja) | 2017-05-31 | 2018-05-30 | ヘテロシクリデンアセトアミド誘導体の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3636640T3 true PL3636640T3 (pl) | 2023-02-27 |
Family
ID=60321089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18810263.6T PL3636640T3 (pl) | 2017-05-31 | 2018-05-30 | Kryształ heterocyklidenowej pochodnej acetamidu |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10208010B2 (pl) |
| EP (1) | EP3636640B1 (pl) |
| JP (1) | JP6230743B1 (pl) |
| KR (1) | KR102576964B1 (pl) |
| CN (1) | CN110831930B (pl) |
| CA (1) | CA3059483A1 (pl) |
| DK (1) | DK3636640T3 (pl) |
| ES (1) | ES2934508T3 (pl) |
| HU (1) | HUE061363T2 (pl) |
| MX (1) | MX2019014216A (pl) |
| PL (1) | PL3636640T3 (pl) |
| PT (1) | PT3636640T (pl) |
| WO (1) | WO2018221543A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6230743B1 (ja) * | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
| AU2020265969A1 (en) * | 2019-04-30 | 2021-12-16 | Beijing Tide Pharmaceutical Co., Ltd. | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
| AU2020361093A1 (en) * | 2019-10-04 | 2022-05-19 | Mochida Pharmaceutical Co., Ltd. | Pharmaceutical drug containing heterocyclidene acetamide derivative |
| KR20230163502A (ko) * | 2021-03-30 | 2023-11-30 | 센주 세이야꾸 가부시키가이샤 | 헤테로시클리덴 아세트아미드 유도체 함유 현탁액 |
| JPWO2024071348A1 (pl) * | 2022-09-29 | 2024-04-04 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101228131B (zh) * | 2005-07-22 | 2013-01-09 | 持田制药株式会社 | 新的杂环亚基乙酰胺衍生物 |
| NZ565080A (en) * | 2005-07-22 | 2011-03-31 | Mochida Pharm Co Ltd | Novel heterocyclidene acetamide derivative |
| JP2011201777A (ja) * | 2008-07-23 | 2011-10-13 | Mochida Pharmaceut Co Ltd | 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体 |
| JP2017108017A (ja) | 2015-12-10 | 2017-06-15 | キヤノン株式会社 | レーザ装置、及びこれを用いた計測装置 |
| JP6230743B1 (ja) * | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
-
2017
- 2017-05-31 JP JP2017108017A patent/JP6230743B1/ja active Active
-
2018
- 2018-05-30 PL PL18810263.6T patent/PL3636640T3/pl unknown
- 2018-05-30 ES ES18810263T patent/ES2934508T3/es active Active
- 2018-05-30 WO PCT/JP2018/020634 patent/WO2018221543A1/ja active Application Filing
- 2018-05-30 HU HUE18810263A patent/HUE061363T2/hu unknown
- 2018-05-30 US US15/993,082 patent/US10208010B2/en active Active
- 2018-05-30 PT PT188102636T patent/PT3636640T/pt unknown
- 2018-05-30 KR KR1020197034846A patent/KR102576964B1/ko active IP Right Grant
- 2018-05-30 MX MX2019014216A patent/MX2019014216A/es unknown
- 2018-05-30 CA CA3059483A patent/CA3059483A1/en active Pending
- 2018-05-30 DK DK18810263.6T patent/DK3636640T3/da active
- 2018-05-30 CN CN201880035532.5A patent/CN110831930B/zh active Active
- 2018-05-30 EP EP18810263.6A patent/EP3636640B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3636640T (pt) | 2022-12-26 |
| KR102576964B1 (ko) | 2023-09-11 |
| RU2019137598A (ru) | 2021-06-30 |
| CN110831930A (zh) | 2020-02-21 |
| HUE061363T2 (hu) | 2023-06-28 |
| DK3636640T3 (da) | 2022-12-19 |
| CA3059483A1 (en) | 2018-12-06 |
| KR20200011943A (ko) | 2020-02-04 |
| RU2019137598A3 (pl) | 2021-07-07 |
| CN110831930B (zh) | 2023-04-28 |
| EP3636640A4 (en) | 2021-03-03 |
| MX2019014216A (es) | 2020-01-23 |
| JP2018203648A (ja) | 2018-12-27 |
| EP3636640B1 (en) | 2022-11-30 |
| JP6230743B1 (ja) | 2017-11-15 |
| WO2018221543A1 (ja) | 2018-12-06 |
| US20180346436A1 (en) | 2018-12-06 |
| ES2934508T3 (es) | 2023-02-22 |
| US10208010B2 (en) | 2019-02-19 |
| EP3636640A1 (en) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279468A (en) | Crystallographic modifications of odeviccibat | |
| GB2542881B (en) | Crystal forms of ß-nicotinamide mononucleotide | |
| IL272888B1 (en) | Uses of piperidinyl-indole derivatives | |
| SI3596042T1 (sl) | Kristalne oblike amino lipidov | |
| IL250391B (en) | Crystalline forms of glutaminase inhibitors | |
| HK1245770A1 (zh) | 尿嘧啶化合物的新型結晶 | |
| IL263050B (en) | History of Subtirum | |
| HUE061363T2 (hu) | Heterociklidén acetamidszármazék kristálya | |
| HK1243418A1 (zh) | 作為roryt調節劑的酰胺取代的噻唑 | |
| IL273463A (en) | Crystalline forms of immunomodulators | |
| HK1244274A1 (zh) | C21h22ci2n4o2的晶型 | |
| IL253018A0 (en) | Crystalline forms of apomorphine and their uses | |
| PL3529236T4 (pl) | Krystaliczne formy erawacykliny | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| IL273430A (en) | crystal | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| IL269792B (en) | Crystalline forms of (s)–apoxolner | |
| HK1244807A1 (zh) | 咪唑衍生物及其中間體的製備方法和晶型 | |
| ZA202100484B (en) | Crystal of benzoxazole derivative | |
| EP3212611A4 (en) | Crystal forms of verapamil hydrochloride | |
| PT3395819T (pt) | Forma cristalina de derivado de aminopirano substituído | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| ZA201901155B (en) | Salt and crystal of diaza-benzofluorane compound | |
| GB201721386D0 (en) | Chrondogy of time-wave | |
| GB201721841D0 (en) | Set of headphones |